Image

HLA B Leader in Patients With Psoriatic Arthritis

HLA B Leader in Patients With Psoriatic Arthritis

Not Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.

Given this association, these diseases are classically regarded as disorders of adaptive immunity.

In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

Eligibility

Inclusion Criteria:

  • For the "Patient" group:
  • Patient over 18 years of age
  • Patient affiliated to a social security scheme
  • Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
  • For the "control" group:
  • Individuals over 18 years of age
  • Individual affiliated to a social security scheme
  • Individual having agreed to participate in the study
  • Individuals with no inflammatory or autoimmune diseases

Exclusion Criteria:

  • Patient or control not understanding French
  • Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
  • Patient or control objecting to participation in the study

Study details
    Psoriatic Arthritis
    HLA b Leader
    HLA B27

NCT07718815

Centre Hospitalier Universitaire, Amiens

10 October 2026

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.